MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Rockwell Medical Total Assets 2011-2026 | RMTI
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Rockwell Medical
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 52.2 M | 46.6 M | 48.6 M | 77.7 M | 44.3 M | 52.6 M | 58.8 M | 83.2 M | 87.8 M | 98 M | 36.4 M | 17 M | 31.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 98 M | 17 M | 56.5 M |
Quarterly Total Assets Rockwell Medical
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 57.5 M | 52.6 M | 59.2 M | 57.1 M | 53 M | 50.7 M | 52.2 M | 52.6 M | 38 M | 40.5 M | 46.6 M | 54.2 M | 59.1 M | 37.4 M | 48.6 M | 58.7 M | 63.7 M | 69.4 M | 77.7 M | 77.7 M | 77.7 M | 77.7 M | 44.3 M | 44.3 M | 44.3 M | 44.3 M | 52.6 M | 52.6 M | 52.6 M | 52.6 M | 58.8 M | 58.8 M | 58.8 M | 58.8 M | 83.2 M | 83.2 M | 83.2 M | 83.2 M | 87.8 M | 87.8 M | 87.8 M | 87.8 M | 98 M | 98 M | 98 M | 98 M | 36.4 M | 36.4 M | 36.4 M | 36.4 M | 17 M | 17 M | 17 M | 17 M | 31.9 M | 31.9 M | 31.9 M | 31.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 98 M | 17 M | 56.9 M |
Total Assets of other stocks in the Drug manufacturers industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
18.2 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
10.9 M | - | 0.86 % | $ 117 M | USA |
 |
Agile Therapeutics
AGRX
|
10.3 M | - | 10.11 % | $ 58.2 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
431 M | - | - | $ 754 M | USA |
 |
Alimera Sciences
ALIM
|
154 M | - | - | $ 142 M | USA |
 |
Canopy Growth Corporation
CGC
|
918 M | $ 1.14 | -4.62 % | $ 123 M |  Canada |
 |
Cronos Group
CRON
|
1.93 B | $ 2.56 | 1.24 % | $ 1.35 B | Canada |
 |
Cumberland Pharmaceuticals
CPIX
|
75.6 M | $ 4.74 | 1.94 % | $ 66.6 M | USA |
 |
Catalent
CTLT
|
9.75 B | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
406 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
5.14 B | - | - | $ 28.9 M |  Irlanda |
 |
Calliditas Therapeutics AB (publ)
CALT
|
1.46 B | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
681 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Evoke Pharma
EVOK
|
7.07 M | - | - | $ 36.6 M | USA |
 |
DURECT Corporation
DRRX
|
45.2 M | - | - | $ 50.1 M | USA |
 |
Emergent BioSolutions
EBS
|
1.82 B | $ 11.08 | 0.82 % | $ 567 M | USA |
 |
Athenex
ATNX
|
204 M | - | -23.39 % | $ 1.76 M | USA |
 |
Evolus
EOLS
|
233 M | $ 5.05 | -2.88 % | $ 313 M | USA |
 |
Harrow Health
HROW
|
312 M | $ 47.49 | -0.86 % | $ 1.55 B | USA |
 |
China Pharma Holdings
CPHI
|
14.9 M | $ 1.25 | - | $ 21.8 M |  China |
 |
Jupiter Wellness
JUPW
|
7.34 M | - | - | $ 33.6 M | USA |
 |
OrganiGram Holdings
OGI
|
408 M | $ 1.62 | 0.62 % | $ 402 M | Canada |
 |
Bausch Health Companies
BHC
|
27.4 B | $ 6.75 | -3.3 % | $ 2.46 B | Canada |
 |
Neoleukin Therapeutics
NLTX
|
223 M | - | - | $ 193 M | Canada |
 |
Lannett Company
LCI
|
484 M | - | 1.15 % | $ 7.11 M | USA |
 |
Sundial Growers
SNDL
|
1.35 B | $ 1.58 | -2.17 % | $ 3.37 M | Canada |
 |
Organogenesis Holdings
ORGO
|
498 M | $ 3.64 | -3.96 % | $ 479 M | USA |
 |
Pacira BioSciences
PCRX
|
1.55 B | $ 19.43 | 1.38 % | $ 899 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
164 M | $ 21.51 | 0.14 % | $ 2.05 B |  France |
 |
PetIQ
PETQ
|
868 M | - | 1.64 % | $ 400 M | USA |
 |
Perrigo Company plc
PRGO
|
9.65 B | $ 15.06 | 0.2 % | $ 2.07 B | USA |
 |
Aurora Cannabis
ACB
|
853 M | $ 4.14 | -2.13 % | $ 86.3 M | Canada |
 |
ProPhase Labs
PRPH
|
87.6 M | - | - | $ 5.07 M | USA |
 |
Recro Pharma
REPH
|
153 M | - | -4.76 % | $ 65.3 M | USA |
 |
Radius Health
RDUS
|
182 M | - | - | $ 1.42 B | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
13.7 M | $ 3.33 | 1.06 % | $ 4.13 M | USA |
 |
Relmada Therapeutics
RLMD
|
97.6 M | $ 3.93 | 5.01 % | $ 118 M | USA |
 |
OptiNose
OPTN
|
108 M | - | - | $ 1.08 B | USA |
 |
Assertio Holdings
ASRT
|
286 M | $ 12.04 | 4.88 % | $ 855 M | USA |
 |
Tilray
TLRY
|
4.31 B | $ 8.74 | -7.62 % | $ 5.4 B | Canada |
 |
PLx Pharma
PLXP
|
76.6 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
189 M | $ 5.59 | 2.19 % | $ 228 M | USA |
 |
SCYNEXIS
SCYX
|
128 M | $ 0.65 | -0.68 % | $ 31.1 M | USA |
 |
Tricida
TCDA
|
169 M | - | - | $ 3.25 M | USA |
 |
Veru
VERU
|
60.4 M | $ 2.53 | -5.95 % | $ 341 M | USA |
 |
TherapeuticsMD
TXMD
|
43.3 M | $ 2.55 | 14.39 % | $ 26.6 M | USA |
 |
Viatris
VTRS
|
50 B | $ 12.66 | -1.59 % | $ 15.3 B | USA |
 |
Zomedica Corp.
ZOM
|
253 M | - | -0.21 % | $ 98 M | USA |
 |
cbdMD
YCBD
|
10.6 M | $ 0.83 | -9.94 % | $ 3.58 M | USA |